WuXi AppTec

Medtec China launches regulatory zone to speed up the internationalization of medical device industry in China; WuXi AppTec confirmed to exhibit

Retrieved on: 
星期二, 五月 29, 2018
Medicine, Medical technology, Technology, WuXi AppTec, Health, Medical device, AppTec, Wuxi

Medtec China, as one of the leading show dedicated in medical device design and manufacturing in China, will be held 26-28 September in Shanghai to continue contributing to accelerate the pace of development.

Key Points: 
  • Medtec China, as one of the leading show dedicated in medical device design and manufacturing in China, will be held 26-28 September in Shanghai to continue contributing to accelerate the pace of development.
  • With the rapid development of Chinese medical device manufacturing, more and more competitive products are being exported to the US, EU and other regions around the world.
  • Exhibitors in REGULATORY STREET provide comprehensive regulatory consultant services including accessing markets in North America, Europe, Japan and Canada.
  • As a leader in the medical device industry for many years, WuXi AppTec provide unique testing plans which can be customized at any stage of the product development life cycle.

WuXi Biologics to Invest S$80 Million to Establish a Biologics Manufacturing Facility in Singapore

Retrieved on: 
星期二, 五月 22, 2018
Biotechnology, Biology, Nature, Wuxi, Yangtze River Delta, Biopharmaceutical, WuXi AppTec

SINGAPORE and SHANGHAI, May 22, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest S$80 million (equivalent to approximately USD$60 million) and hire approximately 150 employees to establish a state-of-the-art biologicsmanufacturing facility in Singapore.It will be the 10th global drug substance manufacturing facility of WuXi Biologics (MFG10).

Key Points: 
  • SINGAPORE and SHANGHAI, May 22, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest S$80 million (equivalent to approximately USD$60 million) and hire approximately 150 employees to establish a state-of-the-art biologicsmanufacturing facility in Singapore.It will be the 10th global drug substance manufacturing facility of WuXi Biologics (MFG10).
  • This state-of-the-art "facility of the future" will be built upon the novel approach WuXi Biologics has pioneered deploying single-use bioreactors.
  • "We are delighted that WuXi Biologics has chosen Singapore as its first overseas manufacturing site in Asia.
  • Dr. Chris Chen, CEO of WuXi Biologics, added, "The new site will undoubtedly meet WuXi Biologics' growing need for biologics development and manufacturing in the near future.

WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

Retrieved on: 
星期三, 五月 16, 2018
Biotechnology, Biology, Nature, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Wuxi, WuXi AppTec

BEIJING, China, May 16, 2018 /PRNewswire/ --WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.

Key Points: 
  • BEIJING, China, May 16, 2018 /PRNewswire/ --WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.
  • Besides serving global clients, the new integrated center will also support Marketing Authorization Holder (MAH) system in China and address urgent needs of Chinese partners.
  • This expansion will allow us great access to local talents, markets and government support," said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.
  • WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.

WuXi STA Announces to Build a New R&D Center in Shanghai

Retrieved on: 
星期五, 四月 27, 2018
WuXi AppTec, Wuxi, Subdivisions of China, Jinshan, Geography of China, Economy of China

SHANGHAI, April 26, 2018 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), announces that it has signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center.

Key Points: 
  • SHANGHAI, April 26, 2018 /PRNewswire/ -- STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), announces that it has signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center.
  • Over the years, WuXi STA has established an industry leading process development platform with over 1,000 scientists and five sites located in China and the United States.
  • WuXi STA's Jinshan site currently focuses on manufacturing innovative Active Pharmaceutical Ingredients (APIs) and advanced intermediates from kilo to metric ton scale.
  • "This new R&D center in Caojing Town, Jinshan is a result of the long term 'win-win' collaboration between Jinshan government and WuXi STA.

Introducing an Internet of DNA for Solving Rare Disease

Retrieved on: 
星期四, 四月 26, 2018
Epidemiology, Rare disease, Genomics, WuXi AppTec

Our success depends on all stakeholders joining together to transform the lives of rare disease families around the world," said Dr Christina Waters, SVP/GM of the global rare disease program at WuXi NextCODE.

Key Points: 
  • Our success depends on all stakeholders joining together to transform the lives of rare disease families around the world," said Dr Christina Waters, SVP/GM of the global rare disease program at WuXi NextCODE.
  • Dr Waters will present the company's strategy and latest progress at the World Orphan Drug Conference , being held outside Washington, DC, at 12:15pm ET today.
  • WuXi NextCODE is a fully integrated contract genomics organization (CGO) building the global standard platform for genomic data.
  • We are also applying the same capabilities to advance a growing range of sequence-based tests and scans in China.

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

Retrieved on: 
星期一, 五月 7, 2018
WuXi AppTec, Health, Food and Drug Administration, Wuxi, Form FDA 483, Biotechnology, Economy of China

SHANGHAI, May 6, 2018 /PRNewswire/ -- STA Pharmaceutical Co., Ltd. , (WuXi STA), a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. Food and Drug Administration (FDA)-- with no Form 483s issued.

Key Points: 
  • SHANGHAI, May 6, 2018 /PRNewswire/ -- STA Pharmaceutical Co., Ltd. , (WuXi STA), a subsidiary of WuXi AppTec, announces that its active pharmaceutical ingredient (API) R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. Food and Drug Administration (FDA)-- with no Form 483s issued.
  • This is the first time that WuXi STA's Changzhou facility has been inspected by the FDA.
  • As a global leading Contract Development and Manufacturing Organization (CDMO), WuXi STA is the first CMC platform (including both APIs and drug product) in China to have passed FDA inspection for new chemical entities.
  • "We are very proud of successfully passing FDA inspection once more," commented Ms. Mei Hao, Vice President of Quality at WuXi STA.

WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services

Retrieved on: 
星期四, 四月 19, 2018
Health, Contract research organizations, Pharmaceutical industry, WuXi AppTec, Drug discovery, Pharmacology, Clinical research, Pre-clinical development, Drug development

After the expansion, LTD's combined New Jersey operation will be one of the largest laboratories for preclinical and clinical drug development testing in the United States.

Key Points: 
  • After the expansion, LTD's combined New Jersey operation will be one of the largest laboratories for preclinical and clinical drug development testing in the United States.
  • "As a renowned global company in life sciences industry, WuXi AppTec is an essential part of New Jersey's pharmaceutical community.
  • The new site will establish a center of excellence for drug development and provide high quality services to the US pharmaceutical and biotech industries.
  • Please visit http://www.wuxiapptec.com
    WuXi AppTec's Laboratory Testing Division is a comprehensive and integrated testing platform for drug and medical device development.